Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity
T2D and obesity are worldwide endemics with millions of people in need of more effective ways to manage their disease.
- T2D and obesity are worldwide endemics with millions of people in need of more effective ways to manage their disease.
- “Type 2 diabetes and obesity are extremely common chronic diseases where the outcome of most therapeutic options is suboptimal.
- “These Phase 2a data provide clinical evidence that duodenal exclusion may be possible with a non-invasive, orally administered, pharmaceutical treatment.
- He will discuss therapeutic targets in the gut for the treatment of T2D and obesity.